Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00545558 · ClinicalTrials.gov registry record · Phase 1

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

A Phase 1 study, sponsored by University of Cincinnati.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT00545558: Completed Phase 1 study, sponsored by University of Cincinnati.

NCT00545558 is a Phase 1 study that has completed, run by University of Cincinnati. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00545558, a Phase 1 study, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.

Interventions

  • DRUG Efavirenz
  • DRUG Emtricitabine/Tenofovir disoproxil fumarate

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2006-04
Est. Completion 2012-03
Phase Phase 1
University of Cincinnati

245 total trials

What the finished NCT00545558 record still lists

NCT00545558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.

NCT00545558 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00545558 about?

NCT00545558 is a clinical study titled "Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV". The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.

What is the current status of trial NCT00545558?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-04. Estimated completion is 2012-03.

What interventions are being tested in trial NCT00545558?

The interventions under investigation include: Efavirenz (DRUG), Emtricitabine/Tenofovir disoproxil fumarate (DRUG).

Who is sponsoring clinical trial NCT00545558?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00545558's enrollment target sits among peer trials

18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00545558, the US trial registry maintained by the National Library of Medicine. NCT00545558 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.